US-based Sensus Healthcare has acquired mobile aesthetic laser companies Aesthetic Mobile Laser Services and Aesthetic Laser Partners in Florida, US.
Both companies were acquired in all-cash transactions. Other financial terms were not disclosed.
The transactions are expected to bring in approximately $1m in revenues over the next 12 months, noted Sensus Healthcare.
The acquired companies together hold 30 lasers and six vans, and service over 150 dermatology practices in Florida, including nearly 500 dermatologists who are not current Sensus customers.
Their lasers provide a range of in-office aesthetic dermatology procedures such as facial rejuvenation, body sculpting / fat removal and wrinkle removal, among other aesthetic applications.
Sensus plans to add the mobile offerings to its aesthetic laser product portfolio, which is expected to obtain US Food and Drug Administration (FDA) 510(k) clearance by the end of this year.
The new lasers use the company’s Sentinel IT Solutions software, which enables asset management and HIPPAA-compliant patient data and storage capability.
Additionally, the Sentinel IT Solutions package consists of software for supporting shared service models, including direct patient billing.
Sensus Healthcare CEO Joe Sardano said: “These acquisitions are the first step in an exciting new and significant growth strategy for Sensus that complements our laser products soon to debut.
“These two established and highly regarded companies offer mobile aesthetic laser units across all of Florida and provide us with access to new dermatology accounts for our superficial radiation therapy (SRT) systems, as well as for an introduction to our new line of lasers expected to be launched later this year.”
As part of the transaction, Sensus has appointed Aesthetic Mobile Laser Services founder Paul Miano as the vice-president of the newly formed division. Aesthetic Laser Partners founder Matthew Hufford has been appointed by the company as the regional manager for Central and Northern Florida.
In 2017, Sensus acquired approval from the China Food and Drug Administration (CFDA) to commercialise its keloid prevention and treatment device SRT-100.
